Ceftazidime-avibactam: new rules for the game against multidrug-resistant gram-negative bacteria | CMAC

Ceftazidime-avibactam: new rules for the game against multidrug-resistant gram-negative bacteria

Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(1):24-34

​ Kozlov R.S., Stetsiouk O.U., Andreeva I.V.
10.36488/cmac.2018.1.24-34
Gram-negative bacteria multidrug resistance beta-lactamase inhibitor ceftazidime-avibactam
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(1):24-34

Abstract

The rapid spread of multidrug-resistant Gram-negative bacteria in hospital settings all over the world makes a demand for the new options to overcome antimicrobial resistance. Ceftazidime-avibactam is the first approved antibiotic that contains a new beta-lactamase inhibitor with unique properties. This review provides insight into the spectrum of activity, pharmacological characteristics, data on efficacy and safety of ceftazidime-avibactam obtained from the clinical trials and real clinical practice, as well as prospects for further studies and clinical application of this new antimicrobial agent.

Roman S. Kozlov

Institute of Antimicrobial Chemotherapy, Smolensk State Medical University, Smolensk, Russia

Olga U. Stetsiouk

Institute of Antimicrobial Chemotherapy, Smolensk State Medical University, Smolensk, Russia

Irina V. Andreeva

Institute of Antimicrobial Chemotherapy, Smolensk State Medical University, Smolensk, Russia

  • 1. Xu Z.Q., Flavin M.T., Flavin J. Combating multidrug-resistant Gramnegative bacterial infections. Expert Opin Investig Drugs. 2014;23:163182.
  • 2. WHO publishes list of bacteria for which new antibiotics are urgently needed. Available at: www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/.
  • 3. Bush K. The ABCD’s of beta-lactamase nomenclature. J Infect Chemother. 2013;19:549-559.
  • 4. Jacoby G.A. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22:161182.
  • 5. Drawz S.M., Bonomo R.A. Three decades of β-lactamase inhibitors. Clin Microbiol Rev. 2010;23:160-201.
  • 6. Papp-Wallace K.M., Bethel C.R., Distler A.M., et al. Inhibitor resistance in the KPC-2 β-lactamase, a preeminent property of this class A β-lactamase. Antimicrob Agents Chemother. 2010;54:890-897.
  • 7. Papp-Wallace K.M., Bonomo R.A. New β-Lactamase inhibitors in the clinic. Infect Dis Clin North Am. 2016;30(2):441-464.
  • 8. Zhanel G.G., Lawson C.D., Adam H., et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013;73:159-177.
  • 9. Levasseur P., Girard A.M., Miossec C., Pace J., Coleman K. In vitro antibacterial activity of the ceftazidime-avibactam combination against Enterobacteriaceae, including strains with well-characterized β-lactamases. Antimicrob Agents Chemother. 2015;59:1931-1934.
  • 10. Levasseur P., Girard A.M., Claudon M., et al. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother. 2012;56:1606-1608.
  • 11. Ehmann D.E., Jahić H., Ross P.L., et al. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci U S A. 2012;109(29):11663-11668.
  • 12. Choi H., Paton R.S., Park H., Schofield C.J. Investigations on recyclisation and hydrolysis in avibactam mediated serine β-lactamase inhibition. Org Biomol Chem. 2016;14(17):4116-4128.
  • 13. Asli A., Brouillette E., Krause K.M., Nichols W.W., Malouin F. Distinctive binding of avibactam to penicillin-binding proteins of Gramnegative and Gram-positive bacteria. Antimicrob Agents Chemother. 2015;60(2):752-756.
  • 14. Miossec C., Claudon M., Levasseur P., Black M.T. The β-lactamase inhibitor avibactam (NXL104) does not induce ampC β-lactamase in Enterobacter cloacae. Infect Drug Resist. 2013;6:235-240.
  • 15. Lucasti C., Popescu I., Ramesh M.K., Lipka J., Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intraabdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother. 2013;68:11831192.
  • 16. Kuzmenkov A.Yu, Trushin I.V, Avramenko A.A., et al. AMRmap: an online platform for monitoring antibiotic resistance. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2017;19(2):84-90. Russian.
  • 17. Sukhorukova M.V., Edelstein M.V., Skleenova E.Yu., et al. Antimicrobial resistance of nosocomial Enterobacteriaceae isolates in Russia: results of multicenter epidemiological study «MARATHON» 20132014. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2017;19(1):49-56. Russian.
  • 18. Edelstein M.V., Sukhorukova M.V., Skleenova E.Yu., et al. Antimicrobial resistance of nosocomial Pseudomonas aeruginosa isolates in Russia: results of multicenter epidemiological study «MARATHON» 20132014. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2017;19(1):37-41. Russian.
  • 19. Ministry of Health of the Russian Federation. Prescribing information for the use of medicinal products for medical use. Zavicefta. Available at: grls.rosminzdrav.ru. Russian.
  • 20. Zasowski T.J., Rybak J.M., Rybak M.J. The β-lactams strike back: ceftazidime-avibactam. Pharmacotherapy. 2015;35(8):755-770.
  • 21. MacVane S.H., Kuti J.L., Nicolau D.P. Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2014;58(3):1359-1364.
  • 22. Drusano G.L. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis. 2003;36(Suppl. 1):S42-S50.
  • 23. Dudley M.N. Combination beta-lactam and beta-lactamase-inhibitor therapy: pharmacokinetic and pharmacodynamic considerations. Am J Health Syst Pharm. 1995;52(6 Suppl. 2):S23-28.
  • 24. Coleman K., Levasseur P., Girard A.M., et al. Activities of ceftazidime and avibactam against beta-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother. 2014;58(6):3366-3372.
  • 25. Vazquez J.A., González Patzán L.D., Stricklin D., et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin. 2012;28(12):1921-1931.
  • 26. Mazuski J.E., Gasink L.B., Armstrong J., et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016;62(11):1380-1389.
  • 27. Wagenlehner F.M., Sobel J.D., Newell P., et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis. 2016;63(6):754-762.
  • 28. Carmeli Y., Armstrong J., Laud P., et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomized, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16:661-673.
  • 29. Torres A., Zhong N., Pachl J., et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 noninferiority trial. Lancet Infect Dis. 2017. pii: S1473-3099(17)30747-8.
  • 30. Das S., Armstrong J., Mathews D., Li J., Edeki T. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamilavibactam. J Clin Pharmacol. 2014;54(3):331-340.
  • 31. U.S. National Library of Medicine. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/results?term=ceftazidime+and+avibactam&Search=Search. Accessed on 28.01.2018.
  • 32. Bradley J.S., Armstrong J., Arrieta A., et al. Phase I study assessing the pharmacokinetic profile, safety, and tolerability of a single dose of ceftazidime-avibactam in hospitalized pediatric patients. Antimicrob Agents Chemother. 2016;60(10):6252-6259.
  • 33. Shields R.K., Potoski B.A., Haidar G., et al. Clinical outcomes, drug toxicity and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2016;63(12):1615-1618.
  • 34. Castón J.J., Lacort-Peralta I., Martín-Dávila P., et al. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. Int J Infect Dis. 2017;59:118-123.
  • 35. Temkin E., Torre-Cisneros J., Beovic B., et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother. 2017;61(2). pii: e0196416.
  • 36. van Duin D., Lok J.J., Earley M., et al. Colistin versus ceftazidimeavibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2018;66(2):163-171.
  • 37. Samuel S., Edwards N., Rojas L., et al. Ceftazidime-avibactam for the treatment of post-neurosurgical meningitis caused by a Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae. Open Forum Infect Dis. 2016;(3 Suppl. 1):1182.
  • 38. Holyk A., Belden V., Lee J.J., et al. Ceftazidime/avibactam use for carbapenem-resistant Klebsiella pneumoniae meningitis: a case report. J Antimicrob Chemother. 2018;73(1):254-256.
  • 39. Wenzler E., Deraedt M.F., Harrington A.T., et al. Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-βlactamase-producing Gram-negative pathogens. Diagn Microbiol Infect Dis. 2017;88:352-354.
  • 40. Davido B., Fellous L., Lawrence C., et al. Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61:e01008-17.
  • 41. Jayol A., Nordmann P., Poirel L., Dubois V. Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2018;73(2):542-544.
  • 42. Shaw E., Rombauts A., Tubau F., et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother. 2018;73(4):1104-1106.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared